In addition, we generated MPNSTs in wild-type mice with Cas9 and sgRNAs targeting Nf1 and Trp53. These models decrease the expense and time to generate primary sarcomas, which should expand the opportunity to employ GEMMs by more investigators in cancer research. This evidence concerns the gene NF1 and sarcoma.